News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
184,361 Results
Type
Article (9780)
Company Profile (22)
Press Release (174559)
Multimedia
Podcasts (17)
Webinars (5)
Section
Business (71224)
Career Advice (330)
Deals (11429)
Drug Delivery (30)
Drug Development (23167)
Employer Resources (41)
FDA (3992)
Job Trends (4129)
News (107428)
Policy (7453)
Tag
2024 BioCapital Digital (3)
2024 Biotech Bay Standard (3)
2024 Biotech Beach Standard (2)
2024 Genetown Standard (1)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
Academia (611)
Accelerated approval (1)
Adcomms (7)
Allergies (18)
Alliances (11742)
ALS (25)
Alzheimer's disease (397)
Antibody-drug conjugate (ADC) (29)
Approvals (4003)
Artificial intelligence (77)
Autoimmune disease (12)
Bankruptcy (119)
Best Places to Work (3336)
BIOSECURE Act (10)
Biosimilars (34)
Biotechnology (19)
Bladder cancer (17)
Brain cancer (6)
Breast cancer (60)
Cancer (655)
Cardiovascular disease (38)
Career advice (287)
Career pathing (6)
CAR-T (44)
Cell therapy (140)
Cervical cancer (4)
Clinical research (19090)
Collaboration (206)
Compensation (104)
Complete response letters (12)
COVID-19 (799)
CRISPR (16)
C-suite (62)
Cystic fibrosis (27)
Data (679)
Denatured (7)
Depression (21)
Diabetes (71)
Diagnostics (1667)
Digital health (7)
Diversity (4)
Diversity, equity & inclusion (12)
Drug discovery (34)
Drug pricing (31)
Drug shortages (6)
Duchenne muscular dystrophy (20)
Earnings (41371)
Editorial (21)
Employer branding (5)
Employer resources (37)
Events (20612)
Executive appointments (229)
FDA (4323)
Featured Employer (4)
Friedreich's ataxia (1)
Frontotemporal dementia (2)
Funding (415)
Gene editing (45)
Generative AI (8)
Gene therapy (92)
GLP-1 (245)
Government (816)
Guidances (29)
Healthcare (5034)
Huntington's disease (9)
IgA nephropathy (9)
Immunology and inflammation (42)
Indications (10)
Infectious disease (837)
Inflammatory bowel disease (34)
Inflation Reduction Act (5)
Influenza (5)
Intellectual property (37)
Interviews (46)
IPO (6189)
IRA (17)
Job creations (927)
Job search strategy (254)
Kidney cancer (1)
Labor market (10)
Layoffs (167)
Leadership (2)
Legal (1504)
Liver cancer (31)
Lung cancer (127)
Lymphoma (56)
Machine learning (1)
Management (9)
Manufacturing (72)
MASH (19)
Medical device (3741)
Medtech (3744)
Mergers & acquisitions (5412)
Metabolic disorders (215)
Multiple sclerosis (23)
NASH (4)
Neurodegenerative disease (34)
Neuropsychiatric disorders (7)
Neuroscience (546)
NextGen: Class of 2025 (1922)
Non-profit (829)
Northern California (856)
Now hiring (2)
Obesity (119)
Opinion (83)
Ovarian cancer (24)
Pain (17)
Pancreatic cancer (40)
Parkinson's disease (32)
Partnered (8)
Patents (50)
Patient recruitment (32)
Peanut (13)
People (14801)
Pharmaceutical (8)
Pharmacy benefit managers (1)
Phase I (5783)
Phase II (8515)
Phase III (6813)
Pipeline (596)
Policy (41)
Postmarket research (517)
Preclinical (2070)
Press Release (9)
Prostate cancer (25)
Psychedelics (8)
Radiopharmaceuticals (41)
Rare diseases (119)
Real estate (1348)
Recruiting (21)
Regulatory (5679)
Reports (8)
Research institute (497)
Resumes & cover letters (43)
Rett syndrome (2)
RNA editing (2)
RSV (16)
Schizophrenia (23)
Series A (103)
Series B (68)
Service/supplier (2)
Sickle cell disease (9)
Southern California (749)
Special edition (5)
Spinal muscular atrophy (49)
Sponsored (5)
Startups (2372)
Stomach cancer (3)
Supply chain (19)
Tariffs (4)
The Weekly (10)
United States (6577)
Vaccines (242)
Venture capitalists (39)
Weight loss (77)
Women's health (7)
Worklife (3)
Date
Today (5)
Last 7 days (128)
Last 30 days (712)
Last 365 days (10390)
2025 (2671)
2024 (11113)
2023 (12709)
2022 (16523)
2021 (16925)
2020 (15530)
2019 (12772)
2018 (9843)
2017 (9367)
2016 (8065)
2015 (9418)
2014 (6917)
2013 (5385)
2012 (5801)
2011 (6371)
2010 (6134)
Location
Africa (185)
Alabama (19)
Alaska (2)
Arizona (42)
Arkansas (6)
Asia (12019)
Australia (1279)
California (1889)
Canada (755)
China (143)
Colorado (78)
Connecticut (78)
Delaware (27)
Europe (22754)
Florida (247)
Georgia (62)
Idaho (12)
Illinois (135)
India (7)
Indiana (75)
Iowa (2)
Japan (82)
Kansas (36)
Kentucky (3)
Louisiana (5)
Maine (34)
Maryland (292)
Massachusetts (1254)
Michigan (77)
Minnesota (86)
Mississippi (1)
Missouri (35)
Montana (7)
Nebraska (4)
Nevada (9)
New Hampshire (19)
New Jersey (607)
New Mexico (8)
New York (520)
North Carolina (236)
Northern California (856)
Ohio (68)
Oklahoma (4)
Oregon (6)
Pennsylvania (340)
Puerto Rico (4)
Rhode Island (1)
South America (272)
South Carolina (3)
Southern California (749)
Tennessee (19)
Texas (232)
Utah (47)
Virginia (21)
Washington D.C. (7)
Washington State (117)
West Virginia (2)
Wisconsin (12)
184,361 Results for "third rock ventures".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Third Rock Ventures Expands Senior Team with Seasoned Biotech Executives
Third Rock Ventures announced today that it has expanded its senior team with the addition and promotion of several industry leaders.
January 25, 2024
·
5 min read
Press Releases
Burning Rock Reports Third Quarter 2024 Financial Results
December 4, 2024
·
17 min read
Press Releases
Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress
November 12, 2024
·
15 min read
Neurodegenerative disease
Scholar Rock’s Shares Soar 300% After Phase III Win in Spinal Muscular Atrophy
With Monday’s data from SAPPHIRE, Scholar Rock is building toward regulatory submissions for apitegromab in spinal muscular atrophy in the first quarter of 2025.
October 8, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
November 4, 2024
·
2 min read
Press Releases
Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress
February 27, 2025
·
18 min read
Press Releases
Scholar Rock to Participate in Upcoming March 2025 Investor Conferences
February 26, 2025
·
2 min read
Press Releases
Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
March 17, 2025
·
13 min read
Genetown
Third Rock Ventures Raises $1.1 Billion Fund VI
Third Rock Ventures today announced the closing of Third Rock Ventures Fund VI, raising $1.1 billion.
June 15, 2022
·
3 min read
Business
Scholar Rock Reports Third Quarter 2023 Financial Results and Highlights Business Progress
Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the third quarter ended September 30, 2023.
November 7, 2023
·
15 min read
1 of 18,437
Next
